Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21951922)

1.

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tokumo H, Hino F, Tazuma S.

Hepatol Res. 2011 Nov;41(11):1057-65. doi: 10.1111/j.1872-034X.2011.00849.x. Epub 2011 Sep 22.

PMID:
21951922
2.

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K.

Hepatol Res. 2012 Nov;42(11):1065-72. doi: 10.1111/j.1872-034X.2012.01034.x. Epub 2012 May 14.

PMID:
22583925
3.

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study.

Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A.

Hepatol Res. 2010 Jun;40(6):566-73. doi: 10.1111/j.1872-034X.2010.00644.x. Epub 2010 Apr 14.

PMID:
20412324
4.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;12:CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
5.

Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study.

Ishitobi T, Hyogo H, Tokumo H, Arihiro K, Chayama K.

Hepatol Res. 2014 Apr;44(4):429-35. doi: 10.1111/hepr.12135. Epub 2013 May 15.

PMID:
23607264
6.

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Verma S, Jensen D, Hart J, Mohanty SR.

Liver Int. 2013 Oct;33(9):1398-405. doi: 10.1111/liv.12226. Epub 2013 Jun 13.

PMID:
23763360
7.

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K.

J Gastroenterol. 2010 Jul;45(7):750-7. doi: 10.1007/s00535-010-0203-y. Epub 2010 Jan 30.

PMID:
20112031
8.

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.

Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K.

Metabolism. 2008 Dec;57(12):1711-8. doi: 10.1016/j.metabol.2008.07.030.

PMID:
19013295
9.

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.

Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS.

Am J Gastroenterol. 2005 May;100(5):1072-81.

PMID:
15842581
10.

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group.

J Hepatol. 2013 Sep;59(3):550-6. doi: 10.1016/j.jhep.2013.04.027. Epub 2013 May 9.

PMID:
23665288
11.

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).

Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD).

Hepatol Res. 2015 Mar;45(3):269-78. doi: 10.1111/hepr.12351. Epub 2014 May 28.

PMID:
24796231
12.

Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients.

Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemsa K, Yasui K, Minami M, Imai S, Itoh Y.

Hepatol Res. 2014 Nov 27. doi: 10.1111/hepr.12456. [Epub ahead of print]

PMID:
25429984
13.

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.

Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL.

Gut. 2010 Jul;59(7):969-74. doi: 10.1136/gut.2009.205088.

PMID:
20581244
14.

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Musso G, Cassader M, Rosina F, Gambino R.

Diabetologia. 2012 Apr;55(4):885-904. doi: 10.1007/s00125-011-2446-4. Epub 2012 Jan 27. Review.

PMID:
22278337
15.

Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.

Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004996. Review.

PMID:
17253535
16.

Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.

Chan WK, Ida NH, Cheah PL, Goh KL.

J Dig Dis. 2014 Oct;15(10):545-52. doi: 10.1111/1751-2980.12175.

PMID:
25060399
17.

[Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].

Watanabe T, Takemura M, Saito K, Ito H, Hattori T, Sekine A, Yamada K, Kato T, Tomita E, Matsuoka T, Seishima M.

Rinsho Byori. 2013 Jan;61(1):19-24. Japanese.

PMID:
23672077
18.

Characteristics and diagnosis of NAFLD/NASH.

Hashimoto E, Taniai M, Tokushige K.

J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. doi: 10.1111/jgh.12271. Review.

PMID:
24251707
19.

Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease.

Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, Sendo R, Mizuno M, Okanoue T.

Hepatol Res. 2015 May;45(5):548-59. doi: 10.1111/hepr.12384. Epub 2014 Aug 13.

PMID:
24976563
20.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk